The Phase 3 clinical trial investigating mavacamten (NCT06253221) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy reached its primary completion on 2025-11-25. This milestone indicates that the collection of primary outcome data for the study has concluded, moving the trial closer to data analysis and potential results dissemination.

Background

The study, officially titled "A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy," aims to assess the efficacy, safety, and pharmacokinetics of mavacamten in this specific patient population. Mavacamten is being investigated as a potential treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition characterized by thickening of the heart muscle that can obstruct blood flow.

Trial design

The trial (NCT06253221) is a Phase 3 study designed to evaluate mavacamten. It enrolled 44 participants who are adolescents diagnosed with symptomatic obstructive hypertrophic cardiomyopathy. The study involves interventions with both mavacamten and a placebo arm, allowing for a comparison of the drug's effects. Currently, the trial status is listed as ACTIVE_NOT_RECRUITING, confirming that participant enrollment is complete and data collection is progressing or has concluded for primary outcomes.

What this means

The primary completion of this Phase 3 trial for mavacamten signifies a crucial step in its development for adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy. With primary data collection concluded, the focus will now shift to analyzing the collected efficacy, safety, and pharmacokinetic data. The results from this study will be essential in determining the potential role of mavacamten as a therapeutic option for this specific population, potentially leading to future regulatory submissions if the data are favorable.

Source

Information regarding the primary completion of this trial was obtained from the ClinicalTrials.gov database. The study record for NCT06253221, titled "A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy," was updated to reflect primary completion on 2025-11-25 on clinicaltrials.gov.